12月8日圣诺生物大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额（万 | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | | | | | 8.23 | 299.98 | 36.45 | -10.13 | 中信证券股份有限公司总部 (非营业场所) | 招商证券股份有限公司 成都人民南路证券营业 | | | | | | | 部 | | 5.50 | 200.48 | 36.45 | -10.13 | 华泰证券股份有限公司深圳深 南大道基金大厦证券营业部 | 招商证券股份有限公司 成都人民南路证券营业 | | | | | | | 部 | | 5.49 | 200.11 | 36.45 | -10.13 | 机构专用 | 招商证券股份有限公司 成都人民南路证券营业 | | | | | | | 部 | 圣诺生物12月8日大宗交易平台共发生3笔成交，合计成交量19.22万股，成交金额700.57万元。成交价格 均为36.45元，相对今日收盘价折价10. ...

| 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-08 | 委诺生物 | 688117 | 36.45 | 299.98 | 8.23 | อลิลิการ | 公司最後大賞為醫 | | Ka | | 2025-12-08 | 圣诺生物 | 688117 | 36.45 | 200.48 | રે રે | 公司 1988年 | 是自己在太后当落 | | KA | | 2025-12-08 | 圣诺生物 | 688117 | 36.45 | 200.11 | 5.49 | 机构专用 | 恐曾是森梵食鳥婴 | | KO | 12月8日，圣诺生物大宗交易成交19.22万股，成交额700.57万元，占当日总成交额的7.67%，成交价 36.45元，较市场收盘价40.56元折价10.13%。 ...

Group 1 - The core announcement is about the successful registration of the cosmetic ingredient Pentapeptide-18 by Chengdu Saintno Biological Technology Co., Ltd. through the National Medical Products Administration [1] - Pentapeptide-18 is a skin protectant that can be used in various cosmetic products, with a safe usage level of up to 1.86% in finished products [1] - The registration enhances the company's product matrix and broadens the application scenarios for beauty peptide products, positively impacting the company's operational development [2] Group 2 - The registration number for Pentapeptide-18 is Guozhuangyuanbeizi 20250152, and it is registered under Chengdu Kaijie Peptide Technology Co., Ltd. [1] - The ingredient is designed to assist in improving skin irritation conditions, thereby achieving skin protection [1]

Core Viewpoint - Shengnuo Bio announced that its wholly-owned subsidiary Chengdu Kaijie Peptide Technology Co., Ltd. has recently obtained the registration of the cosmetic raw material Pentapeptide-18 from the National Medical Products Administration, indicating a significant advancement in the company's product offerings in the cosmetic industry [1] Group 1: Product Development - Pentapeptide-18 is a skin protectant that can be used in various cosmetic products [1] - The safe usage level of Pentapeptide-18 in finished cosmetic products can reach 1.86% [1] - The ingredient aids in improving skin irritation conditions, thereby achieving skin protection [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2025-037 成都圣诺生物科技股份有限公司 关于自愿披露五肽-18 通过化妆品新原料备案的公告 成都圣诺生物科技股份有限公司（以下简称"公司"）全资子公司成都凯捷 多肽科技有限公司的化妆品原料五肽-18 于近日通过国家药品监督管理局化妆 品新原料备案，现将相关情况公告如下： 一、化妆品原料基本情况 中文名称：五肽-18 INCI 名称：PENTAPEPTIDE-18 备案号：国妆原备字 20250152 备案人：成都凯捷多肽科技有限公司 二、化妆品原料的其他情况 公司本次备案成功的化妆品新原料五肽-18 是一种可用于各类化妆品的皮 肤保护剂，在化妆品成品中的安全使用量可达 1.86%。通过协助改善皮肤刺激状 态等，从而达到皮肤保护的作用。 三、对公司的影响 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次五肽-18 通过化妆品新原料备案，将进一步完善公司产品矩阵，拓宽美 容多肽类产品的应用场景，对公司经营发展具有一定的积极作用。 四、风险提示 由于化妆品产品的行 ...

Core Viewpoint - Shengnuo Bio (688117.SH) announced that its wholly-owned subsidiary Chengdu Kaijie Peptide Technology Co., Ltd. has successfully registered a new cosmetic ingredient, Pentapeptide-18, with the National Medical Products Administration, indicating a significant advancement in the company's product offerings in the cosmetic sector [1] Group 1: Company Developments - The new cosmetic ingredient Pentapeptide-18 is a skin protectant that can be used in various cosmetic products [1] - The safe usage concentration of Pentapeptide-18 in finished cosmetic products can reach up to 1.86% [1] - The ingredient is designed to assist in improving skin irritation conditions, thereby achieving skin protection [1]

Group 1 - The core point of the article is that Shengnuo Bio's subsidiary, Chengdu Kaijie Peptide Technology Co., Ltd., has successfully registered a new cosmetic ingredient, Pentapeptide-18, with the National Medical Products Administration [1] - Pentapeptide-18 is a skin protectant that can be used in various cosmetic products, with a safe usage level of up to 1.86% in finished products [1] - The approval of Pentapeptide-18 will enhance the company's product portfolio and expand the application scenarios for beauty peptide products, positively impacting the company's business development [1]

Group 1 - The core point of the announcement is the election of the fifth board of directors for Chengdu Saintno Biological Technology Co., Ltd., which will consist of 9 members, including 6 non-independent directors and 3 independent directors [1][2] - The board has proposed candidates for the fifth board, including Mr. Wen Yongjun, Ms. Wang Xiaoli, Mr. Yu Xiaohai, Mr. Wu Li, Mr. Yang Guanglin, and Mr. Zeng Dezhi as non-independent directors, and Mr. Xu Zhengsong, Ms. Liu Xia, and Mr. He Zekai as independent directors [1][2] - The election will be conducted at the first extraordinary shareholders' meeting of 2025, using a cumulative voting system, and the independent directors' qualifications must be approved by the Shanghai Stock Exchange before the meeting [2][3] Group 2 - The candidates for the fifth board meet the qualifications required by relevant laws and regulations, and none of them are disqualified from serving as directors [3][5][6] - The current board has been diligent and has contributed positively to the company's operations and development [3] - The fifth board will assume office upon approval at the shareholders' meeting, with a term of three years [2][3] Group 3 - The first extraordinary shareholders' meeting of 2025 is scheduled for December 17, 2025, and will utilize the Shanghai Stock Exchange's online voting system [17][18] - The meeting will combine on-site and online voting methods, with specific time slots for voting [19][20] - Shareholders must register to attend the meeting, and detailed registration procedures are provided [24][25]

成都圣诺生物科技股份有限公司董事会提名委员会 关于提名公司第五届董事会非独立董事候选人的审查意见 余啸海 2025 年12月1 日 （本页无正文,为《成都圣诺生物科技股份有限公司董事会提名委员会关于提名 公司第五届董事会非独立董事候选人的审查意见》签字页) 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交 易所科创板股票上市规则》等法规以及《成都圣诺生物科技股份有限公司章程》 等公司制度的规定，我们作为成都圣诺生物科技股份有限公司（以下简称"公司"） 第四届董事会提名委员会委员，本着对公司及全体股东负责的态度，基于审慎独 立判断的立场，认真审核了公司非独立董事候选人文永均先生、王晓莉女士、余 啸海先生、伍利先生、杨广林先生、曾德志先生的个人履历等相关资料，现就提 名文永均先生、王晓莉女士、余啸海先生、伍利先生、杨广林先生、曾德志先生 为公司第五届董事会非独立董事候选人事项发表审查意见如下： 公司第五届非独立董事会董事候选人文永均先生、王晓莉女士、余啸海先生、 伍利先生、杨广林先生、曾德志先生符合担任公司董事的任职条件，具备履行董 事职责的能力，不存在《公司法》《上海证券交易所科创板股票上市规 ...

独立董事提名人声明与承诺 提名人成都圣诺生物科技股份有限公司董事会,现提名徐正 松为成都圣诺生物科技股份有限公司第五届董事会独立董事候 选人,并已充分了解被提名人职业、学历、职称、详细的工作经 历、全部兼职、有无重大失信等不良记录等情况。被提名人已书 面同意出任成都圣诺生物科技股份有限公司第五届董事会独立 董事候选人(参见该独立董事候选人声明)。提名人认为,被提 名人具备独立董事任职资格,与成都圣诺生物科技股份有限公司 之间不存在任何影响其独立性的关系,具体声明并承诺如下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、 行政法规、规章及其他规范性文件,具有五年以上法律、经济、 会计、财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规 定: (二)《中华人民共和国公务员法》关于公务员兼任职务的 规定; (三)中国证监会《上市公司独立董事管理办法》、上海证 拳交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定; ...